Thermo Fisher Scientific Adds Patterned Microchip-based Technology to Liquid Chromatography Portfolio

November 1, 2021 |

2 min read

ASMS 2021 -- Thermo Fisher Scientific, the world leader in serving science, today announced its acquisition of Belgium -based PharmaFluidics, the developer of the μPAC range of micro-chip-based chromatography columns.

Extends capabilities in column performance for biopharma and proteomics researchers

[01-November-2021]

PHILADELPHIA, Nov. 1, 2021 /PRNewswire/ -- ASMS 2021 -- Thermo Fisher Scientific, the world leader in serving science, today announced its acquisition of Belgium-based PharmaFluidics the developer of the μPAC range of micro-chip-based chromatography columns.

The µPAC portfolio of columns enhance liquid chromatography (LC) performance in biomarker, proteomics and drug research and development applications, helping biotechnology and pharmaceutical companies uncover new insights and advance scientific discovery. Through an innovative approach, separation performance and sensitivity are improved with the μPAC chromatography columns, allowing for the identification of substantially more compounds in complex biological samples. The μPAC portfolio acquisition complements Thermo Fisher’s existing chromatography solutions to deliver extended analytical capabilities to researchers.

“LC is a key analytical technique across numerous applications, and its accuracy, reproducibility and robustness is critical to the delivery of meaningful results,” said Kent Davidson, vice president and general manager, high performance chromatography solutions, chromatography and mass spectrometry, Thermo Fisher Scientific. “Columns are an essential part of these workflows, and the next-generation μPAC columns push this element to a new level through innovative pillar array technology, improving the quality of data.”

The μPAC columns deliver excellent separation and sensitivity to achieve greater identifications from samples with a large dynamic range, ultimately enhancing the solutions available for pharmaceutical laboratories to help meet changing needs in medical research.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.